Patents by Inventor Jared A. Gollob

Jared A. Gollob has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • IRAK4 DEGRADERS AND USES THEREOF
    Publication number: 20250082645
    Abstract: The present invention provides IRAK4 degraders, formulations and unit dosage forms thereof, and methods of use thereof.
    Type: Application
    Filed: November 21, 2024
    Publication date: March 13, 2025
    Inventors: Jared Gollob, Jeffrey Davis, Alice McDonald, Haojing Rong
  • STAT3 DEGRADERS AND USES THEREOF
    Publication number: 20250019388
    Abstract: The present invention relates to STAT3 degraders, their liquid formulations, and methods of use thereof for treating cancer.
    Type: Application
    Filed: September 24, 2024
    Publication date: January 16, 2025
    Inventors: Sagar Agarwal, Christopher De Savi, Joyoti Dey, Vaishali Dixit, Bradley Enerson, Ashwin Gollerkeri, Jared Gollob, Chris Ho, Michele Mayo, Haojing Rong, Bin Yang
  • IRAK4 degraders and uses thereof
    Patent number: 12171768
    Abstract: The present invention provides IRAK4 degraders, formulations and unit dosage forms thereof, and methods of use thereof.
    Type: Grant
    Filed: February 15, 2022
    Date of Patent: December 24, 2024
    Assignee: Kymera Therapeutics, Inc.
    Inventors: Jared Gollob, Jeffrey Davis, Alice Mcdonald, Haojing Rong
  • COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING STARGARDT'S DISEASE AND/OR RETINAL BINDING PROTEIN 4 (RBP4)-ASSOCIATED DISORDERS
    Publication number: 20240309375
    Abstract: The present invention relates to agents which inhibit the expression and/or activity of transthyretin (TTR), e.g., a double stranded RNA (dsRNA) agent, or salt thereof, or an antisense oligonucleotide or a gene therapy targeting TTR, and the use of these agents in methods of treating or preventing Startgardt's disease, methods of decreasing Vitamin A levels or formation of toxic Vitamin A metabolites, and/or methods of halting progression of vision loss in a subject. The present invention also relates to RNAi agents, e.g., double stranded RNA (dsRNA) agents, targeting the retinal binding protein 4 (RBP4) gene. The invention also relates to methods of using such RNAi agents to inhibit expression of an RBP4 gene. The invention further provides the use of RNAi agent targeting RBP4 and/or nucleic acid agents targeting TTR in methods of preventing and treating an RBP4-associated disorder, e.g., an ocular disease, e.g., Stargardt's disease, diabetic retinopathy, age-related macular degeneration (AMD), e.g.
    Type: Application
    Filed: December 7, 2023
    Publication date: September 19, 2024
    Inventors: Jared A. Gollob, Kevin Fitzgerald, David Erbe, Simina Ticau, Jeffrey Zuber
  • GNAQ targeted dsRNA compositions and methods for inhibiting expression
    Patent number: 12031133
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) targeting a G-alpha q subunit (GNAQ) of a heterotrimeric G gene, and methods of using the dsRNA to inhibit expression of GNAQ.
    Type: Grant
    Filed: February 9, 2021
    Date of Patent: July 9, 2024
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Jared Gollob, Gregory Hinkle, Ivanka Toudjarska, David Bumcrot
  • DOSAGES AND METHODS FOR DELIVERING LIPID FORMULATED NUCLEIC ACID MOLECULES
    Publication number: 20240175024
    Abstract: Methods, kits and devices for dosing a subject to reduce a hypersensitivy response to a lipid-formulated nucleic acid (e.g., RNA) molecule are disclosed.
    Type: Application
    Filed: October 18, 2023
    Publication date: May 30, 2024
    Inventors: Pia Kasperkovitz, Jared A. Gollob
  • COMPOSITIONS AND METHODS FOR TREATING TRANSTHYRETIN (TTR) MEDIATED AMYLOIDOSIS
    Publication number: 20240075052
    Abstract: Disclosed herein are methods for treating hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis) in a human patient in need thereof by administering an effective amount of a transthyretin (TTR)-inhibiting composition.
    Type: Application
    Filed: September 28, 2023
    Publication date: March 7, 2024
    Inventor: Jared A. Gollob
  • Dosages and methods for delivering lipid formulated nucleic acid molecules
    Patent number: 11827883
    Abstract: Methods, kits and devices for dosing a subject to reduce a hypersensitivy response to a lipid-formulated nucleic acid (e.g., RNA) molecule are disclosed.
    Type: Grant
    Filed: April 8, 2021
    Date of Patent: November 28, 2023
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Pia Kasperkovitz, Jared Gollob
  • Compositions and methods for treating transthyretin (TTR) mediated amyloidosis
    Patent number: 11806360
    Abstract: Disclosed herein are methods for treating hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis) in a human patient in need thereof by administering an effective amount of a transthyretin (TTR)-inhibiting composition.
    Type: Grant
    Filed: September 19, 2018
    Date of Patent: November 7, 2023
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventor: Jared Gollob
  • IRAK4 DEGRADERS AND USES THEREOF
    Publication number: 20230277519
    Abstract: The present invention relates to IRAKIMiD degraders, their liquid formulations, and methods of use thereof for treating cancer.
    Type: Application
    Filed: January 13, 2023
    Publication date: September 7, 2023
    Inventors: Jared Gollob, Jeffrey Davis, Ashwin Gollerkeri, Reginald EWESUEDO, Alice McDonald, Vashali Dixit, Shu-Pei Wu, Michele Mayo, Haojing Rong, Sagar Agarwal, Bradley Enerson, Patrick Henrick, Rachelle Perea, Christopher Ho, William Leong, Duncan Walker
  • IRAK DEGRADERS AND USES THEREOF
    Publication number: 20230241075
    Abstract: The present invention provides methods for identifying or selecting a patient having an elevated level of an inflammatory biomarker, and methods for treating a disease or disorder in a patient comprising selecting a patient having an elevated level of an inflammatory biomarker, and administering to the patient an IRAK degrader.
    Type: Application
    Filed: June 17, 2021
    Publication date: August 3, 2023
    Inventors: Veronica CAMPBELL, Alice MCDONALD, Jared GOLLOB, Anthony SLAVIN
  • GNAQ Targeted dsRNA Compositions and Methods for Inhibiting Expression
    Publication number: 20220348915
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) targeting a G-alpha q subunit (GNAQ) of a heterotrimeric G gene, and methods of using the dsRNA to inhibit expression of GNAQ.
    Type: Application
    Filed: February 9, 2021
    Publication date: November 3, 2022
    Inventors: Jared Gollob, Gregory Hinkle, Ivanka Toudjarska, David Bumcrot
  • IRAK4 DEGRADERS AND USES THEREOF
    Publication number: 20220273668
    Abstract: The present invention provides IRAK4 degraders, formulations and unit dosage forms thereof, and methods of use thereof.
    Type: Application
    Filed: February 15, 2022
    Publication date: September 1, 2022
    Inventors: Jared GOLLOB, Jeffrey DAVIS, Alice MCDONALD, Haojing RONG
  • DOSAGES AND METHODS FOR DELIVERING LIPID FORMULATED NUCLEIC ACID MOLECULES
    Publication number: 20210388355
    Abstract: Methods, kits and devices for dosing a subject to reduce a hypersensitivy response to a lipid-formulated nucleic acid (e.g., RNA) molecule are disclosed.
    Type: Application
    Filed: April 8, 2021
    Publication date: December 16, 2021
    Inventors: Pia Kasperkovitz, Jared Gollob
  • Compositions and Methods for Treating Transthyretin (TTR) Mediated Amyloidosis
    Publication number: 20210361692
    Abstract: Disclosed herein are methods for treating hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis) in a human patient in need thereof by administering an effective amount of a transthyretin (TTR)-inhibiting composition.
    Type: Application
    Filed: September 19, 2018
    Publication date: November 25, 2021
    Inventor: Jared Gollob
  • GNAQ targeted dsRNA compositions and methods for inhibiting expression
    Patent number: 10954516
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) targeting a G-alpha q subunit (GNAQ) of a heterotrimeric G gene, and methods of using the dsRNA to inhibit expression of GNAQ.
    Type: Grant
    Filed: April 3, 2018
    Date of Patent: March 23, 2021
    Assignee: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: Jared Gollob, Gregory Hinkle, Ivanka Toudjarska, David Bumcrot
  • DOSAGES AND METHODS FOR DELIVERING LIPID FORMULATED NUCLEIC ACID MOLECULES
    Publication number: 20190284557
    Abstract: Methods, kits and devices for dosing a subject to reduce a hypersensitivy response to a lipid-formulated nucleic acid (e.g., RNA) molecule are disclosed.
    Type: Application
    Filed: January 29, 2019
    Publication date: September 19, 2019
    Inventors: Pia Kasperkovitz, Jared Gollob
  • GNAQ Targeted dsRNA Compositions and Methods for Inhibiting Expression
    Publication number: 20190106694
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) targeting a G-alpha q subunit (GNAQ) of a heterotrimeric G gene, and methods of using the dsRNA to inhibit expression of GNAQ.
    Type: Application
    Filed: April 3, 2018
    Publication date: April 11, 2019
    Inventors: Jared Gollob, Gregory Hinkle, Ivanka Toudjarska, David Bumcrot
  • Dosages and methods for delivering lipid formulated nucleic acid molecules
    Patent number: 10246708
    Abstract: Methods, kits and devices for dosing a subject to reduce a hypersensitivity response to a lipid-formulated nucleic acid (e.g., RNA) molecule are disclosed.
    Type: Grant
    Filed: May 6, 2014
    Date of Patent: April 2, 2019
    Assignee: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: Pia Kasperkovitz, Jared Gollob
  • GNAQ targeted dsRNA compositions and methods for inhibiting expression
    Patent number: 9963700
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) targeting a G-alpha q subunit (GNAQ) of a heterotrimeric G gene, and methods of using the dsRNA to inhibit expression of GNAQ.
    Type: Grant
    Filed: December 21, 2016
    Date of Patent: May 8, 2018
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Jared Gollob, Gregory Hinkle, Ivanka Toudjarska, David Bumcrot